Adjuvant chemotherapy for non-small cell lung cancer.
Adjuvant chemotherapy for non-small cell lung cancer.
复制标题
DOI：
10.1007/s11864-006-0031-8
复制
发表时间：
2006-01-01
影响因子：
4.3
通讯作者：
Simon, George
中科院分区：
文献类型：
--
作者：
Crane, Edward J;Simon, George
在20世纪80年代和90年代早期，非小细胞肺癌（NSCLC）辅助化疗的研究并未提供一致的无病生存期或总生存期获益。然而，最近报道的研究已经改变了NSCLC治疗的实践，辅助化疗现在被认为是治疗的标准。本综述概述了可能限制早期试验中辅助化疗有益效果检测的问题，并对最近发表的NSCLC辅助化疗试验结果进行了详细分析。
Studies of adjuvant chemotherapy for non-small cell lung cancer (NSCLC) did not provide a consistent disease-free survival or overall survival benefit in the 1980s and early 1990s. However, recently reported studies have changed the practice of NSCLC treatment, for which adjuvant chemotherapy is now considered the standard of care. This review outlines the issues that may have limited the detection of beneficial effects of adjuvant chemotherapy in early trials and provides detailed analysis of the results of recently published trials of adjuvant chemotherapy for NSCLC.